雷珠单抗联合微脉冲激光对视网膜分支静脉阻塞继发黄斑水肿的疗效评估  

Evaluation of the effect of micropulse laser photocoagulation combined with ranibizumab in the treatment of secondary ME caused by retinal branch vein occlusion

作　　者：王雪[1] 姜海涛[1] 任增金 WANG Xue;JIANG Hai-tao;REN Zeng-jin(Ophthalmology Department of Lianyungang First People’s Hospital,Lianyungang 222000,China)

机构地区：[1]连云港市第一人民医院眼科,江苏连云港222000

出　　处：《中国药物应用与监测》2023年第6期394-397,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的:探讨黄斑区微脉冲激光联合雷珠单抗治疗视网膜分支静脉发生阻塞(BRVO)继发黄斑水肿(ME)的疗效评估。方法:本研究采用回顾性数据分析,选取自2020年2月-2022年12月连云港市第一人民医院90例BRVO继发ME患者(全部是单眼患病),按照其治疗手段的不同分成2组,对照组(45例)实施玻璃体腔注射雷珠单抗治疗,研究组(45例)实施玻璃体腔注射雷珠单抗联合黄斑区微脉冲激光治疗。比较2组患者治疗后1、3、6个月的临床疗效等差异。结果:两组治疗后1、3、6个月BCVA、CMT均低于治疗前,其中对照组治疗后3、6个月均低于治疗后1个月,而研究组治疗后1、3、6个月各个时间点间比较,差异均有统计学意义(均P<0.05);此外,治疗后6个月研究组BCVA(0.29±0.05)、CMT(205.37±13.84)均低于对照组(0.40±0.06,236.58±15.07),差异有统计学意义(P<0.05)。研究组治疗6个月内雷珠单抗注射次数(3.51±0.88)少于对照组(4.25±1.02),差异具有统计学意义(P<0.05),而两组复发率对比,差异无统计学意义(P>0.05)。治疗后两组的并发症发生率比较,差异无统计学意义(P>0.05)。结论:临床上对于BRVO继发ME的患者实施黄斑区微脉冲激光联合雷珠单抗治疗效果较好,值得临床推广应用。Objective:To assess the effectiveness of rabizumab combined with macular micropulse laser for the therapy of macular edema(ME)resulting from branch retinal vein occlusion(BRVO)Methods:Retrospective data analysis was used in this study,from February 2020 to December 2022,90 patients with ME secondary to BRVO in Lianyungang First People’s Hospital hospital(all of them suffered from monocular disease)were selected and divided into the two group according to the different treatment methods.The control group(45 cases)received intravitreal injection of ranibizumab,while the study group(45 cases)received ranibizumab combined with macular micropulse laser photocoagulation.45 patients in the control group were treated with intravitreal injection of ranibizumab,while ranibizumab in conjunction with retinal laser photocoagulation was administered to 45 participants in the study group.The clinical effects of the two groups were compared at 1,3and 6 months after treatment.Results:The BCVA and CMT of the two groups at 1,3,and 6 months after treatment were lower than those before treatment.The BCVA and CMT of the control group at 3 and 6 months after treatment were lower than those at 1 month after treatment,while the BCVA and CMT of the study group at 3 and 6 months after treatment were lower than those at 1 month after treatment.While there were differences among different time points in study group at 1,3,and 6 months after treatment(P<0.05).In addition,BCVA(0.29±0.05)and CMT(205.37±13.84)in the study group were lower than those in the control group 6 months after treatment(0.40±0.06,236.58±15.07),and the difference was statistically significant(P<0.05).The number of ranibizumab injections in the study group(3.51±0.88)within 6 months of treatment was less than that in the control group(4.25±1.02),the difference was statistically significant(P<0.05),while the recurrence rate of 2 groups was not statistically obvious(P>0.05).There was no difference in the incidence of complications between 2 groups after treatment(P>0.

关 键 词：微脉冲激光 雷珠单抗 视网膜分支静脉阻塞 黄斑水肿 疗效 

分 类 号：R774.5[医药卫生—眼科]